Full Press Release Details
Alcon Receives FDA Approval of TRIESENCE Injectable Triamcinolone Suspension for Use in Eye
HUENENBERG, Switzerland
November 30, 2007 Alcon (NYSE:ACL) announced today that the
United States Food and Drug Administration (FDA) has approved TRIESENCE
(triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic
corticosteroid for visualization during vitrectomy and treatment of sympathetic ophthalmia,
temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical
The active ingredient in TRIESENCE , triamcinolone acetonide, has been
used for many years to treat retinal disease. This new approval brings ophthalmologists a
sterile, preservative-free formulation of the compound specifically developed for use in
the eye to treat various retinal inflammatory conditions.
TRIESENCE injectable suspension is a synthetic corticosteroid
indicated for treatment of the following ophthalmic diseases: sympathetic ophthalmia,
temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical
corticosteroids. TRIESENCE is also indicated for visualization during vitrectomy.
For complete product information, see product insert.
inflammation most commonly occurs in response to infection, allergy, surgery or trauma
(i.e., blow to the eye, foreign body, chemical injury). Uveitis, one form of eye
inflammation treatable with TRIESENCE , is one of the more common types of
inflammation. With uveitis, the uveal tract of the eye, including the
iris, the ciliary body and
the choroid, becomes inflamed. This can result
from ocular trauma or an existing systemic disease. In typical uveitis the patient
experiences eye pain, photophobia and excessive
tearing. Sufferers report a deep, dull aching of the eye and surrounding area. While
haziness may be present, visual acuity is not usually impaired to any great
is a type of eye surgery in which some or all of the vitreous humor is removed from the
eye. This type of surgery is often performed in patients with diabetic retinopathy, a
detached retina, a macular hole or other conditions. TRIESENCE assists retinal
surgeons with visualization during these types of surgery.
is the world's leading eye care company, with sales of approximately $4.9 billion in 2006.
Alcon, which has been dedicated to the ophthalmic industry for 60 years, researches,
develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact
lens care solutions and other vision care products that treat diseases,
and other conditions of the eye. Alcon's majority shareholder is Nestle, S.A., the world's
largest food company. For more information on Alcon Inc., visit the company s web
site at www.alcon.com.
Concerning Forward-Looking Statements. This press release contains
forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995. These statements involve known and unknown risks, uncertainties and other
factors which may cause our actual results, performance or achievements to be materially
different from any future results, performances or achievements expressed or implied by our
forward-looking statements. These statements reflect the views of our management as of the
date of this press release with respect to future events and are based on assumptions and
subject to risks and uncertainties. Given these uncertainties, you should not place undue
reliance on these forward-looking statements. You should read this press release with the
understanding that our actual future results may be materially different from what we
expect. Except to the extent required under the federal securities laws and the rules an
regulations promulgated by the Securities and Exchange Commission, we undertake no
obligation to publicly update or revise any of these forward-looking statements, whether to
reflect new information or future events or circumstances or otherwise.
information, contact:
Clark (Strategic Corporate Communications)